DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
PAHC logo

Phibro Animal Health Corporation Stock Price

NasdaqGM:PAHC Community·US$1.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PAHC Share Price Performance

US$34.68
-3.72 (-9.69%)
​
US$45.60
Fair Value
US$34.68
-3.72 (-9.69%)
23.9% undervalued intrinsic discount
US$45.60
Fair Value
Price US$34.68
AnalystConsensusTarget US$45.60
AnalystLowTarget US$35.00
AnalystHighTarget US$58.00
Thu, 4 Jun 26
Fair ValueUS$45.60
Share Pricen/a

PAHC Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$45.6 23.9% undervalued intrinsic discount

Feed Additives And Vaccines Will Shape Global Market Amid Headwinds

1users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$35 Fairly Valued intrinsic discount

Rising Plant-Based Trends And Global Regulations Will Harm Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$58 40.2% undervalued intrinsic discount

Asia And Latin America Will Drive Secular Animal Health Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PAHC logo
Phibro Animal Health
Fairly Valued intrinsic discount

Rising Plant-Based Trends And Global Regulations Will Harm Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 29 Jul
Read Narrative
PAHC logo
Phibro Animal Health
40.2% undervalued intrinsic discount

Asia And Latin America Will Drive Secular Animal Health Demand

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 18 Jun
Read Narrative
PAHC logo
Phibro Animal Health
23.9% undervalued intrinsic discount

Feed Additives And Vaccines Will Shape Global Market Amid Headwinds

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 4 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
PAHC logo

PAHC: Future Returns Will Hinge On Regulatory Risks And Execution Against Guidance

Fair Value: US$35 Fairly Valued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
PAHC logo

PAHC: Strong Earnings And Insider Buying Will Support Forward Repricing

Fair Value: US$58 40.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
PAHC logo

PAHC: Regulatory Reset And Sustainability Platform Will Shape Future Upside Potential

Fair Value: US$45.6 23.9% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Solid track record, good value and pays a dividend.

2 Risks
3 Rewards
View Full Analysis

Phibro Animal Health Corporation Key Details

US$1.5b

Revenue

US$1.0b

Cost of Revenue

US$506.0m

Gross Profit

US$406.3m

Other Expenses

US$99.7m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
2.46
33.33%
6.57%
191.9%
View Full Analysis

About PAHC

Founded
1946
Employees
2605
CEO
Daniel Bendheim
WebsiteView website
www.pahc.com

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

Recent PAHC News & Updates

Seeking Alpha • Aug 30

Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead

Summary Phibro Animal Health’s Zoetis MFA acquisition has created a larger animal health platform with stronger earnings and broader manufacturing reach. Vaccines, nutritional specialties, and companion-animal expansion give PAHC newer growth verticals beyond the legacy MFA franchise. Management’s optimization program and Chicago Heights consolidation could improve efficiency as the acquired portfolio moves beyond integration. Given that PAHC stock is now cheaper after the recent pullback, I feel this is a great “Buy” zone for long-term investors. Read the full article on Seeking Alpha

Recent updates

No updates

Phibro Animal Health Corporation Competitors

PRAX logo

Praxis Precision Medicines

Symbol: NasdaqGS:PRAX
Market cap: US$8.3b
TGTX logo

TG Therapeutics

Symbol: NasdaqCM:TGTX
Market cap: US$8.1b
SYRE logo

Spyre Therapeutics

Symbol: NasdaqGS:SYRE
Market cap: US$8.0b
IMVT logo

Immunovant

Symbol: NasdaqGS:IMVT
Market cap: US$7.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide